CapsoVision Aims for Growth with Next-Gen Capsule Endoscopy & Colon Cancer Screening Tech

NEW YORK, NY – November 20, 2025

CapsoVision, Inc. (NASDAQ: CV) is actively engaging with investors at the Benchmark 14th Annual Discovery One-on-One Investor Conference, signaling a continued push for growth and market adoption of its advanced capsule endoscopy technology. The medical device company is highlighting recent successes with its CapsoCam Plus® system, while also providing updates on the development of CapsoCam Colon™, a potentially groundbreaking non-invasive colon cancer screening tool.

Expanding the Reach of Wireless Capsule Endoscopy

CapsoVision is rapidly gaining traction in the competitive gastrointestinal imaging market. Its core product, CapsoCam Plus®, utilizes a wire-free, panoramic capsule endoscope, offering patients a more comfortable and less invasive alternative to traditional methods of small bowel imaging. The company’s success is driven by several key differentiators, including a 360-degree panoramic view and extended battery life – features that improve diagnostic yield and patient experience.

“The demand for less invasive diagnostic procedures is growing significantly,” says one industry analyst. “Patients are increasingly seeking options that minimize discomfort and risk, and CapsoCam Plus directly addresses that need.”

The company has reported impressive growth in utilization, with over 151,000 patients having undergone procedures using CapsoCam Plus as of September 30, 2025—a substantial increase from the previous quarter. This success is also reflected in the company’s revenue, which has demonstrated a consistent year-over-year increase, reaching $3.5 million in Q3 2025. However, despite this growth, CapsoVision is still operating at a net loss, reflecting the high costs associated with research and development, as well as the expenses of being a publicly traded company.

CapsoVision isn't alone in this space; established players like Medtronic (PillCam™) and Olympus offer competing capsule endoscopy systems. However, CapsoVision believes its unique features and ongoing innovation – including the integration of AI-assisted image analysis – position it for continued market share gains. The company is actively exploring ways to expand the application of its technology to other areas of the gastrointestinal tract.

The Promise of Non-Invasive Colon Cancer Screening

Beyond its established product, CapsoVision is generating significant excitement with the development of CapsoCam Colon™. Colon cancer remains a leading cause of cancer-related deaths, but early detection is crucial for improving outcomes. Traditional colonoscopies, while effective, can be uncomfortable, require extensive bowel preparation, and carry a small risk of complications. CapsoCam Colon™ aims to address these challenges by offering a non-invasive alternative.

“If successful, this could be a game-changer for colon cancer screening,” notes one healthcare innovation expert. “A non-invasive option could significantly increase screening rates, particularly among individuals who are hesitant to undergo a colonoscopy.”

The company submitted a 510(k) notification to the FDA for CapsoCam Colon™ in June 2025, marking a critical step towards potential market authorization. A pivotal clinical trial (NCT04607746) is currently evaluating the safety and effectiveness of the technology, with results expected to support the regulatory submission. The trial is focused on demonstrating the accuracy of CapsoCam Colon™ in detecting colonic polyps—precancerous growths that can develop into cancer.

While a specific timeline for FDA approval remains uncertain, CapsoVision is optimistic about the potential of CapsoCam Colon™ to disrupt the colon cancer screening landscape. The company is also exploring potential applications of its technology in other areas, such as detecting early-stage pancreatic cancer and esophageal varices.

Navigating a Competitive Landscape and Future Growth

CapsoVision’s participation in the Benchmark conference underscores its commitment to securing investment and raising awareness among potential shareholders. The company is competing for capital in a crowded healthcare innovation space, but analysts believe its differentiated technology and clear vision for the future position it well for success.

“The company is executing on its strategy,” says another industry observer. “They've demonstrated the ability to innovate, secure regulatory approvals, and generate revenue. The key now is to scale up operations and expand into new markets.”

The company’s stock currently carries a consensus rating of “Moderate Buy” from Wall Street analysts, with an average price target of $6.00 per share. While challenges remain, CapsoVision’s commitment to innovation and its growing presence in the rapidly evolving field of gastrointestinal imaging suggest a promising future. The company’s ability to continue developing and commercializing groundbreaking technologies will be crucial for driving long-term growth and delivering value to shareholders and, ultimately, improving patient care.